These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8940032)

  • 1. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
    J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW; van Vlijmen BJ; de Winther MP; van 't Hof B; van der Zee A; van der Boom H; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW; van Vlijmen BJ; van der Zee A; van't Hof B; van der Boom H; Kobayashi K; Chan L; Havekes LM; Hofker MH
    Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):7-12. PubMed ID: 9445249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia.
    van den Maagdenberg AM; Hofker MH; Krimpenfort PJ; de Bruijn I; van Vlijmen B; van der Boom H; Havekes LM; Frants RR
    J Biol Chem; 1993 May; 268(14):10540-5. PubMed ID: 7683682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.
    Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA
    J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells.
    Ji ZS; Brecht WJ; Miranda RD; Hussain MM; Innerarity TL; Mahley RW
    J Biol Chem; 1993 May; 268(14):10160-7. PubMed ID: 7683668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van den Maagdenberg AM; Gijbels MJ; van der Boom H; HogenEsch H; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1994 Apr; 93(4):1403-10. PubMed ID: 8163645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE.
    van Dijk KW; van Vlijmen BJ; van't Hof HB; van der Zee A; Santamarina-Fojo S; van Berkel TJ; Havekes LM; Hofker MH
    J Lipid Res; 1999 Feb; 40(2):336-44. PubMed ID: 9925664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice.
    Mensenkamp AR; van Luyn MJ; van Goor H; Bloks V; Apostel F; Greeve J; Hofker MH; Jong MC; van Vlijmen BJ; Havekes LM; Kuipers F
    J Hepatol; 2000 Aug; 33(2):189-98. PubMed ID: 10952236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; Mensink RP; van 't Hof HB; Offermans RF; Hofker MH; Havekes LM
    J Lipid Res; 1998 Jun; 39(6):1181-8. PubMed ID: 9643349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia.
    Fazio S; Marotti KR; Lee YL; Castle CK; Melchior GW; Rall SC
    J Biol Chem; 1994 Dec; 269(51):32368-72. PubMed ID: 7798236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E.
    Veinbergs I; Van Uden E; Mallory M; Alford M; McGiffert C; DeTeresa R; Orlando R; Masliah E
    Exp Neurol; 2001 Jul; 170(1):15-26. PubMed ID: 11421580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.
    Tacken PJ; Beer FD; Vark LC; Havekes LM; Hofker MH; Willems Van Dijk K
    Biochem J; 2000 Apr; 347(Pt 2):357-61. PubMed ID: 10749663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.